These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

10392 related items for PubMed ID: 19891279

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. HDL-C: role as a risk modifier.
    Barter P.
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G, Maggioni AP.
    Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
    [Abstract] [Full Text] [Related]

  • 7. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z.
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. How to control residual cardiovascular risk despite statin treatment: focusing on HDL-cholesterol.
    Lim S, Park YM, Sakuma I, Koh KK.
    Int J Cardiol; 2013 Jun 05; 166(1):8-14. PubMed ID: 22503572
    [Abstract] [Full Text] [Related]

  • 11. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.
    Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C, European Consensus Panel on HDL-C.
    Curr Med Res Opin; 2004 Aug 05; 20(8):1253-68. PubMed ID: 15324528
    [Abstract] [Full Text] [Related]

  • 12. The therapeutic role of niacin in dyslipidemia management.
    Boden WE, Sidhu MS, Toth PP.
    J Cardiovasc Pharmacol Ther; 2014 Mar 05; 19(2):141-58. PubMed ID: 24363242
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M, Roberts A, Davies S, Rees A.
    Drugs; 2004 Mar 05; 64(11):1181-96. PubMed ID: 15161326
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ, Yellon DM.
    Heart; 2008 Jun 05; 94(6):706-14. PubMed ID: 18480348
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 520.